Compare EDSA & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDSA | UGRO |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 1.9M |
| IPO Year | 2018 | 2018 |
| Metric | EDSA | UGRO |
|---|---|---|
| Price | $6.95 | $2.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 7.2M | 59.3K |
| Earning Date | 02-13-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,008,850.00 |
| Revenue This Year | N/A | $98.41 |
| Revenue Next Year | N/A | $23.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.11 |
| 52 Week High | $8.74 | $4.50 |
| Indicator | EDSA | UGRO |
|---|---|---|
| Relative Strength Index (RSI) | 67.33 | 48.27 |
| Support Level | $1.71 | $2.12 |
| Resistance Level | $8.74 | $3.41 |
| Average True Range (ATR) | 1.55 | 0.30 |
| MACD | 0.15 | -0.10 |
| Stochastic Oscillator | 65.62 | 5.56 |
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).